OKYO Pharma Limited (OKYO) NASDAQ
1.70
-0.01(-0.58%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.70
-0.01(-0.58%)
Currency In USD
Address
55 Park Lane
London, W1K 1NA
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 20 7495 2379
Website
Sector
Healthcare
Industry
Biotechnology
Employees
3
First IPO Date
May 17, 2022
| Name | Title | Pay | Year Born |
| Robert J. Dempsey | Chief Executive Officer & Executive Director | 450,000 | N/A |
| Gary S. Jacob | Chief Development Officer & Director | 450,000 | 1947 |
| Flavio Mantelli | Chief Medical Officer | 0 | N/A |
| Rajkumar Patil | Chief Scientific Officer | 0 | 1959 |
| Michael Paul Beck | Founder | 0 | 1957 |
| Keeren Shah | Chief Financial Officer | 0 | 1976 |
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.